CMMB
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
17.9M
GET INTRADAY SIGNALS
CMMB Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
50 days until earnings call
+Compare
CMMB
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
17.9M

CMMB Price Prediction, Chemomab Therapeutics Ltd AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
CMMB Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 21, 2023

CMMB in +10.20% Uptrend, advancing for three consecutive days on March 21, 2023

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CMMB advanced for three days, in 148 of 165 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CMMB's RSI Oscillator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where CMMB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on March 21, 2023. You may want to consider a long position or call options on CMMB as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CMMB just turned positive on March 20, 2023. Looking at past instances where CMMB's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

CMMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

CMMB moved below its 50-day moving average on February 22, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CMMB entered a downward trend on March 21, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.494) is normal, around the industry mean (21.860). P/E Ratio (0.000) is within average values for comparable stocks, (125.771). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.743). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (305.824).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

CMMB is expected to report earnings to fall 14.29% to -2 cents per share on March 20

Chemomab Therapeutics Ltd CMMB Stock Earnings Reports
Q4'22
Est.
$-0.03
Q3'22
Beat
by $0.20
Q2'22
Beat
by $0.15
Q1'22
Beat
by $0.15
Q4'21
Beat
by $0.08
The last earnings report on November 11 showed earnings per share of -3 cents, beating the estimate of -23 cents. With 59.00K shares outstanding, the current market capitalization sits at 17.90M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.94B. The market cap for tickers in the group ranges from 160 to 319.16B. NONOF holds the highest valuation in this group at 319.16B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -2%. BXPHF experienced the highest price growth at 200%, while MMIRF experienced the biggest fall at -92%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -25% and the average quarterly volume growth was -73%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 61
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a provider of biopharmaceutical services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Kiryat Atidim
Phone
+972 773310156
Employees
20
Web
https://www.chemomab.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STNE9.570.64
+7.17%
StoneCo Ltd
MNSB23.380.68
+3.00%
MainStreet Bancshares
MOV33.320.73
+2.24%
Movado Group
AMS2.840.03
+1.07%
American Shared Hospital Services
XYL98.520.87
+0.89%
Xylem

CMMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMMB has been loosely correlated with AXON. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMMB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMMB
1D Price
Change %
CMMB100%
+8.72%
AXON - CMMB
37%
Loosely correlated
+2.79%
SPRB - CMMB
36%
Loosely correlated
+0.43%
DTIL - CMMB
33%
Loosely correlated
+2.41%
NOVN - CMMB
33%
Loosely correlated
+12.86%
HARP - CMMB
33%
Loosely correlated
-0.67%
More